Literature DB >> 12568309

Low-dose antithymocyte globulin for treatment of steroid-pulse-resistant acute graft-versus-host disease.

Kazuteru Ohashi, Yuji Tanaka, Shin-ichiro Mori, Yoshiki Okuyama, Kiyoshi Hiruma, Hideki Akiyama, Hisashi Sakamaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12568309     DOI： 10.1007/BF02982612

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

1.  Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience.

Authors:  N Basara; M G Kiehl; W Blau; E Römer; M Bischoff; B Schmetzer; D Kirsten; S Günzelmann; A A Fauser
Journal:  Transplant Proc       Date:  2001-05       Impact factor: 1.066

2.  Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin.

Authors:  H Khoury; A Kashyap; D R Adkins; R A Brown; G Miller; R Vij; P Westervelt; K Trinkaus; L T Goodnough; R J Hayashi; P Parker; S J Forman; J F DiPersio
Journal:  Bone Marrow Transplant       Date:  2001-05       Impact factor: 5.483

Review 3.  ATG plus corticosteroid therapy for acute graft-versus-host disease: predictors of response and survival.

Authors:  M J Dugan; T E DeFor; M Steinbuch; A H Filipovich; D J Weisdorf
Journal:  Ann Hematol       Date:  1997 Jul-Aug       Impact factor: 3.673

4.  IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade.

Authors:  P A Rowlings; D Przepiorka; J P Klein; R P Gale; J R Passweg; P J Henslee-Downey; J Y Cahn; S Calderwood; A Gratwohl; G Socié; M M Abecasis; K A Sobocinski; M J Zhang; M M Horowitz
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

5.  Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

Authors:  R A Nash; J H Antin; C Karanes; J W Fay; B R Avalos; A M Yeager; D Przepiorka; S Davies; F B Petersen; P Bartels; D Buell; W Fitzsimmons; C Anasetti; R Storb; V Ratanatharathorn
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

6.  Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin.

Authors:  K G McCaul; T J Nevill; M J Barnett; C L Toze; C J Currie; H J Sutherland; E A Conneally; J D Shepherd; S H Nantel; D E Hogge; H G Klingemann
Journal:  J Hematother Stem Cell Res       Date:  2000-06

7.  Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone.

Authors:  H J Deeg; T P Loughran; R Storb; M S Kennedy; K M Sullivan; K Doney; F R Appelbaum; E D Thomas
Journal:  Transplantation       Date:  1985-08       Impact factor: 4.939

8.  Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: a multicentric pilot study including 15 patients.

Authors:  E Racadot; N Milpied; P Bordigoni; J Y Cahn; E Plouvier; B Lioure; P Lutz; J Wijdenes; P Herve
Journal:  Bone Marrow Transplant       Date:  1995-05       Impact factor: 5.483
  8 in total
  4 in total

Review 1.  Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns.

Authors:  Koichi Miyamura
Journal:  Int J Hematol       Date:  2016-01-12       Impact factor: 2.490

2.  A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease.

Authors:  Chie Onishi; Kazuteru Ohashi; Takeshi Sawada; Mikako Nakano; Takeshi Kobayashi; Takuya Yamashita; Hideki Akiyama; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2010-03-10       Impact factor: 2.490

Review 3.  Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.

Authors:  Makoto Murata
Journal:  Int J Hematol       Date:  2015-04-12       Impact factor: 2.490

4.  Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT.

Authors:  M Murata; K Ikegame; Y Morishita; H Ogawa; K Kaida; H Nakamae; T Ikeda; T Nishida; M Inoue; T Eto; K Kubo; T Sakura; T Mori; N Uchida; T Ashida; Y Matsuhashi; Y Miyazaki; T Ichinohe; Y Atsuta; T Teshima
Journal:  Bone Marrow Transplant       Date:  2016-11-21       Impact factor: 5.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.